Welcome to our dedicated page for Grail SEC filings (Ticker: GRAL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GRAIL, Inc. (Nasdaq: GRAL) files reports with the U.S. Securities and Exchange Commission that provide detail on its operations as a healthcare diagnostics company focused on multi-cancer early detection. On this page, you can review GRAIL’s SEC filings, including current reports on Form 8-K that describe material events such as private placements, equity distribution agreements, commercial leases, preliminary financial results, and strategic collaboration arrangements.
Recent 8-K filings outline securities purchase agreements for private placements of common stock and pre-funded warrants, a stock purchase agreement with Samsung-related entities tied to a planned business collaboration for commercialization of the Galleri test in Asia, and an equity distribution agreement that allows at-the-market offerings of common stock through designated sales agents. Other filings describe a long-term lease for a new corporate headquarters in Sunnyvale, California and the release of quarterly financial results, along with the company’s use of non-GAAP measures such as Adjusted Gross Profit (Loss) and Adjusted EBITDA.
Through these filings, investors can see how GRAIL structures its financings, the key terms of its strategic agreements, and selected information about its financial condition and operations. Stock Titan’s platform adds AI-powered summaries that explain the main points of each filing in plain language, highlight important sections, and help distinguish between one-time transactions and ongoing obligations. Users can also quickly locate information related to equity issuances, registration rights, and other matters that may affect existing or prospective shareholders.
GRAIL, Inc. is a commercial-stage healthcare company focused on multi-cancer early detection using its Galleri blood test, which looks for abnormal DNA methylation patterns to detect a cancer signal and predict the cancer signal of origin. Galleri can screen for over 50 cancer types, many without existing screening guidelines, and has been used in more than 475,000 commercial tests as of December 31, 2025.
The company highlights large interventional trials. PATHFINDER 2 showed a positive predictive value of 61.6%, a cancer signal origin accuracy of 92%, a 0.4% false positive rate, and a more than seven-fold increase in cancers found when added to recommended screenings. The randomized NHS-Galleri Trial did not meet its primary endpoint of reducing combined stage 3 and 4 cancers, but showed substantial reductions in stage 4 diagnoses (greater than 20% in the second and third screening rounds), more stage 1–2 cancers, and a four-fold increase in detection versus standard screening alone.
In January 2026 GRAIL submitted a premarket approval application to the FDA for Galleri using NHS-Galleri and PATHFINDER 2 data and a bridging analysis. A February 2026 law created a future Medicare coverage category for FDA-approved multi-cancer early detection tests, with potential national coverage beginning January 1, 2029 for ages 50–65. Key risks include a history of significant net losses, heavy dependence on Galleri for revenue, uncertainty around FDA approval, reimbursement and guideline inclusion, perpetual high single-digit royalties owed to Illumina, reliance on sole suppliers for core inputs, and substantial clinical, regulatory and implementation uncertainty despite strong trial signals.
GRAIL, Inc.'s Chief Financial Officer, Aaron Freidin, reported automatic tax-related stock sales. On March 5 and March 9, he sold a total of 3,147 shares of GRAIL common stock in open-market transactions ranging from $46.74 to $53.01 per share.
According to the disclosure, these were automatic "sell-to-cover" trades executed by a broker to cover withholding taxes when equity awards vested and shares were delivered, rather than discretionary portfolio sales. After these transactions, Freidin directly owned 306,475 shares of GRAIL common stock.
GRAIL, Inc. President Joshua J. Ofman reported automatic sales of 3,627 shares of common stock to cover taxes on vested awards. According to the filing, an executing broker sold shares in block trades on March 5 and March 9, 2026 at weighted average prices of $53.01, $47.93, and $46.74 per share. After these sell-to-cover transactions, Ofman directly owned 432,881 shares of GRAIL common stock.
GRAIL, Inc. director and Chief Executive Officer Robert P. Ragusa reported sales of a total of 8,441 shares of common stock in open-market transactions. The sales occurred on March 5 and March 9, 2026 at prices ranging from $46.73 to $53.01 per share.
According to the footnote, these were automatic “sell-to-cover” trades executed by a broker to cover withholding taxes upon award vesting and share delivery, and the reported prices are weighted averages for multiple trades. After these transactions, Ragusa directly holds 642,084 shares of GRAIL common stock.
GRAL submitted a Form 144 notice reporting proposed affiliate sales and recent RSU vestings. The filing lists a proposed sale of 9,573 shares on 03/02/2026 for $480,244.38. It also shows shares acquired upon RSU vesting: 1,261 on 03/04/2026 and 4,669 on 03/06/2026.
ETRADE FINANCIAL CORPORATION reported insider share movements: a previously reported sale of 37,504 common shares by Robert P. Ragusa on 03/02/2026, and the issuer recorded restricted stock unit vestings of 1,891 shares on 03/04/2026 and 14,006 shares on 03/06/2026.
The filing lists the securities as Common Stock on NASDAQ and shows the shares were acquired upon vesting under the issuer's equity incentive plans for services rendered.
Joshua J. Ofman reported a proposed sale of 17,002 shares of common stock by notice on 03/02/2026, with an aggregate value of $852,847.77. The filing also lists restricted stock units that vested into 1,329 shares on 03/04/2026 and 5,502 shares on 03/06/2026 as issuances by the issuer for services rendered.
Shares outstanding were 40,990,388 as of 03/05/2026.
GRAIL, Inc. president Joshua J. Ofman reported a mix of equity awards and tax-related share sales. He received an award of 84,540 restricted stock units, which will vest in four substantially equal annual installments beginning on February 28, 2027, with each unit settling into one share of common stock upon vesting.
On March 2, 2026, an executing broker sold a total of 17,002 shares of common stock in automatic “sell-to-cover” transactions to satisfy withholding taxes upon award vesting, at weighted average prices of $51.7509 and $50.0853 per share. After these sales, Ofman directly owned 436,508 shares of common stock. His reported holdings were also adjusted to include 152 additional dividend shares received in connection with the GRAIL spin-off from Illumina.
GRAIL, Inc. reported that Chief Financial Officer Aaron Freidin received an award of 60,118 restricted stock units on February 27, 2026. These RSUs will vest in four substantially equal annual installments beginning on February 28, 2027, and each unit will settle into one share of common stock when vested.
On March 2, 2026, an executing broker carried out automatic sell-to-cover transactions totaling 9,573 shares of common stock at weighted average prices of $50.0853 and $51.8611 to cover withholding taxes tied to award vesting and share delivery. After these transactions, Freidin directly held 309,622 shares of GRAIL common stock.
GRAIL, Inc. director and Chief Executive Officer Robert P. Ragusa reported two automatic sell-to-cover transactions of common stock tied to equity award vesting. He disposed of 35,787 shares at an average price of $50.0853 and 1,717 shares at $51.8430 to cover withholding taxes.
After these tax-related sales, he continued to hold 650,525 shares of GRAIL common stock directly. The prices reported represent weighted average prices calculated by the executing broker for block trades executed in multiple transactions.